Physician profile
Mark K Ray
NPI 1720022874
$7,471.27
in general payments reported to CMS, 2019-2025
38 companies · $962 in 2025
The $962 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $1,404 · 2021: $410 · 2022: $754 · 2023: $1,204 · 2024: $963 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.85 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,141.87 | 2019-2025 | Ilumya |
| Abbvie INC. | $882.16 | 2019-2025 | |
| Janssen Biotech, INC. | $830.88 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $548.83 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $502.90 | 2019-2025 | |
| Genzyme Corporation | $472.53 | 2020-2024 | |
| Lilly USA, LLC | $429.13 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $389.50 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $294.44 | 2019-2025 | Dupixent |
| Incyte Corporation | $269.30 | 2022-2025 | Opzelura |
| Ucb, INC. | $268.67 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.41 | 2019-2024 | Siliq |
| Galderma Laboratories, L.P. | $175.74 | 2019-2025 | Nemluvio |
| Allergan, INC. | $159.92 | 2019-2020 | |
| Dermira, INC. | $116.65 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $75.30 | 2019-2024 | Klisyri |
| Celgene Corporation | $70.91 | 2019 | |
| Mayne Pharma Commercial LLC | $61.37 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.24 | 2022-2025 | Sotyktu |
| Mission Pharmacal Company | $48.79 | 2020-2022 | |
| Pfizer INC. | $45.40 | 2019-2022 | |
| Dermavant Sciences, INC. | $45.17 | 2023 | Vtama |
| Epi Health, LLC | $44.01 | 2019 | |
| Botanix Sb INC | $42.61 | 2025 | Sofdra |
| Boston Scientific Corporation | $38.46 | 2022 | |
| Genentech USA, INC. | $31.66 | 2021-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2022 | |
| Tempus Ai, INC | $23.28 | 2024 | Merlin Test |
| Helsinn Therapeutics (U.S.), INC. | $19.51 | 2022 | |
| Journey Medical Corporation | $19.07 | 2022 | |
| Lnhc, INC | $18.37 | 2025 | Zelsuvmi |
| Taro Pharmaceuticals USA, INC. | $18.33 | 2019 | |
| Prugen, INC. Pharmaceuticals | $18.17 | 2020 | |
| Cipher Pharmaceuticals US LLC | $16.87 | 2025 | Natroba, Spinosad |
| Leo Pharma INC. | $16.59 | 2019 | |
| Vyne Pharmaceuticals INC. | $16.03 | 2020 | |
| Sebela Pharmaceuticals INC. | $12.70 | 2020 | |
| Aclaris Therapeutics, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.